Iambic Therapeutics, Inc is a biotechnology company that develops AI-driven platforms to accelerate the discovery of novel medicines for serious diseases. Its work sits at the intersection of physics-informed machine learning, high-throughput experimental automation, and drug discovery, with a focus on oncology and pharmaceuticals.
The company's central offering is the Iambic Platform, which integrates its proprietary AI and automation capabilities to design, synthesize, and test drug candidates. The platform is designed to deliver new drug candidates to human clinical trials at what the company describes as industry-leading speed.
Iambic's pipeline includes several therapeutic programs. IAM1363, a HER2 inhibitor, is currently in Phase 1/1b clinical studies. The company is also developing a selective dual CDK2/4 inhibitor for cancer indications and programs targeting novel mechanisms of action, including allosteric inhibition for KIF18A. Its proprietary technologies, NeuralPLexer and Enchant, are also used in strategic partnerships.
